Takeda Pharmaceutical Co - ADR
TAK
Market Cap$41.65B
Close$
Earnings Call Q5 2023
February 2, 2024 - AI Summary
Takeda's revenue for FY 2023 Q3 was flat compared to the previous year at constant exchange rates, but grew by 4.6% on an actual basis due to FX benefits.
The company's growth and launch products represented 43% of total revenue and achieved a growth rate of 12.7% at constant exchange rates.
Core operating profit declined by 9.3% at constant exchange rates, primarily due to generic competition impacting high-margin products and lower COVID-19 vaccine revenue.
Exclusive for Stockcircle Pro members
Sign up
$320.64
2323.6% upside
Current Fair Value
2323.6% upsideUndervalued by 2323.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $41.65 Billion |
|---|---|
| Enterprise Value | $78.28 Billion |
| Dividend Yield | $0.3191 (2.42%) |
| Earnings per Share | $0.42 |
| Beta | 0.39 |
| Outstanding Shares | 3,164,817,650 |
| Avg 30 Day Volume | 1,833,896 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 31.34 |
|---|---|
| PEG | -179.17 |
| Price to Sales | 1.47 |
| Price to Book Ratio | 0.88 |
| Enterprise Value to Revenue | 2.6 |
| Enterprise Value to EBIT | 23.74 |
| Enterprise Value to Net Income | 58 |
| Total Debt to Enterprise | 0.49 |
| Debt to Equity | 0.81 |
Revenue Sources
No data
ESG Score
No data
About Takeda Pharmaceutical Co
CEO: Christophe Weber